摘要
目的探讨外周血中前列腺特异性抗原(PSA)和前列腺干细胞抗原(PSCA)单独或联合检测对于前列腺癌的临床诊断价值。方法选取100名健康者(非患者组)、91例前列腺增生患者(BPH组)和84例前列腺癌患者(PCA组)作为研究对象,采用酶联免疫吸附试验检测各组血清中PSA和PSCA的含量,并采用受试者工作特征(ROC)曲线评价单独或联合检测PSA和PSCA对前列腺癌的诊断价值。结果 BPH组和PCA组血清中PSA和PSCA含量显著高于非患者组(P<0.01),PCA组中PSA和PSCA含量显著高于BPH组(P<0.01)。PSA、PSCA单独或联合检测区分非患者和BPH患者的ROC曲线下面积分别为0.690(95%CI为0.615~0.766),0.700(95%CI为0.673~0.814)和0.898(95%CI为0.854~0.943),表明两指标单独或联合检测对于BPH患者具有一定的诊断意义;区分非患者和PCA患者的曲线下面积分别为0.867(95%CI为0.813~0.921),0.904(95%CI为0.858~0.951)和0.973(95%CI为0.944~1.000),表明PSA、PSCA单独或联合检测对于PCA诊断具有较高的价值;区分BPH患者和PCA患者的曲线下面积分别为0.687(95%CI为0.608~0.766),0.818(95%CI为0.752~0.884)和0.862(95%CI为0.803~0.920),表明在区分BPH和PCA的诊断中,二者单独检测均具有一定价值,且联合检测具有较高的临床诊断意义。结论血清PSA和PSCA单独或联合检测对于BPH和PCA均具有临床诊断价值,并且联合检测的诊断价值更高。
Objective To investigate the clinical value of prostate-specific antigen （PSA） and prostate stem cell antigen （PSCA） in peripheral blood alone or in combination for the clinical diagnosis of prostate cancer.Methods 100 healthy people （non-patient group）, 91 patients with benign prostatic hyperplasia （BPH group） and 84 patients with prostate cancer （PCA group） were selected.The levels of PSA and PSCA were measured by enzyme-linked immunosorbent assay.The diagnostic value of PSA and PSCA alone or in combination for the diagnosis of prostate cancer was evaluated using the receiver operating characteristics （ROC） curve.Results The levels of PSA and PSCA in BPH group and PCA group were significantly higher than those in non-patients group （P〈0.01）, and the levels of PSA and PSCA in PCA group were significantly higher than those in BPH group （P〈0.01）.The area under the ROC curve for PSA and PSCA alone or in combination to distinguish between non-patients and BPH patients were 0.690（95%CI 0.615-0.766）, 0.700（95%CI 0.673-0.814） and 0.898（95%CI 0.854-0.954） respectively,indicating that the two indicators alone or in combination had a certain diagnostic significance for BPH patients;the area to distinguish between non-patients and PCA patients were 0.867（95%CI 0.813-0.921）, 0.904（95%CI 0.858-0.951） and 0.973（95%CI 0.944-1.000） respectively, which indicated that the detection of PSA, PSCA alone or in combination had a high diagnostic significance for PCA;the area to distinguish between BPH patients and PCA patients were 0.687（95%CI 0.608-0.766）, 0.818（95%CI 0.752-0.884） and 0.862（95%CI 0.803-0.920）, respectively, indicating that for the distinction between BPH and PCA in the diagnosis, PSA or PSCA alone had a certain diagnostic significance, and the combined detection had a higher clinical significance.Conclusion Both serum PSA and PSCA alone or in combination have significant clinical diagnosis values for both BPH and PCA, and the diagnostic value of combined detection is higher.
作者
王志
廖有刚
申凯
辛宇鹏
WANG Zhi LIAO You-gang SHEN Kai XIN Yu-peng(Department of Urology ,Jiangyou people＇s Hospital, Jiangyou 621700, China Department of Urology, Mianyang Central Hospital of Sichuan,Mianyang 621099,China)
出处
《标记免疫分析与临床》
CAS
2017年第9期1018-1021,共4页
Labeled Immunoassays and Clinical Medicine
关键词
前列腺癌
前列腺增生
前列腺特异性抗原
前列腺干细胞抗原
联合检测
受试者工作特征曲线
临床诊断
Prostate cancer
Benign prostatic hyperplasia
Prostate-specific antigen
Prostate stem cell antigen
Combined detection
Receiver operating characteristic curve
Clinical diagnosis
